Tsingke Links AI Molecular Design to Automated Lab Manufacturing
Tsingke Biotech is integrating scalable molecular synthesis, high-throughput experimentation and laboratory automation to connect AI-driven designs with real-world testing. The Beijing-based company says the work supports a data-driven approach to molecular research and development.
- Tsingke is advancing its “AI + Molecular Manufacturing” strategy.
- Its automated oligonucleotide platform combines synthesis, purification, analysis and dispensing systems.
- The company is aligning its roadmap with self-driving laboratory workflows.
- AI can prioritize candidates while automated systems produce samples and run experiments.
- Tsingke offers DNA and RNA synthesis, gene cloning, protein expression and viral vector packaging.
A manufacturing bridge for molecular design
Tsingke said on Nov. 5 that it is advancing its “AI + Molecular Manufacturing” strategy. The company, which provides nucleic acid and gene synthesis solutions, is combining automated manufacturing with experimental systems intended to produce and evaluate molecular candidates at scale.
According to Tsingke, its automated manufacturing platform uses robotics and precision workflows to bridge AI molecular designs with high-throughput laboratory validation. The company has more than a decade of experience in nucleic acid and gene synthesis, including synthesis equipment, process engineering, production scale-up, digitalization and automated manufacturing.
Its capabilities range from micromole-scale synthesis to gram-scale production and, for applicable processes, hundreds of grams to kilograms. Tsingke said these operations are supported by process control and quality management.
Automation spans synthesis and testing
Tsingke’s fully automated oligonucleotide platform brings together synthesizers, ammonolysis systems, purification systems, microplate readers and automated dispensing systems. A six-axis robotic arm, high-precision linear rails and centralized control coordinate the workflow from phosphoramidite-based synthesis through to finished oligonucleotide products.
The company also applies automation to PCA product preparation, sequencing, and nucleic acid extraction and purification. Tsingke says these systems support experimental consistency, traceability and structured data collection, giving researchers a more connected record of how samples are produced, processed and analyzed.
That connection is central to the company’s approach. Linking sample identities, experimental conditions, process parameters and analytical results can provide the structured information needed to compare experiments and feed results into later research decisions.
Toward self-driving laboratory workflows
Tsingke’s roadmap aligns with self-driving laboratories, or SDLs, where automated experiments and data-driven decisions guide successive research cycles. The company describes the cycle as: “Design → Build → Test/Screen → Learn → Next Round.”
In this model, AI can prioritize candidates for testing, while automated systems support sample production and experiments. The resulting data can then inform subsequent design decisions. Tsingke said experimental results do more than validate predictions, because they help shape the next stage of the research process.
For researchers, the announcement points to an effort to connect molecular design, manufacturing and laboratory validation within a single feedback loop. Tsingke said its manufacturing and automation capabilities provide a foundation for more integrated, AI-enabled laboratory workflows, although the announcement did not provide performance figures or a launch timeline for a specific product.
What Tsingke provides
Beijing Tsingke Biotech Co., Ltd. describes itself as a biotechnology company serving research and therapeutic development. Its offerings include custom DNA and RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging for AAV, LV and AdV.
The company said its ISO 13485-certified facilities and Class 100,000 cleanroom support consistent quality and reliability. Tsingke added that its automation capabilities and global scientific team support work in drug discovery, functional genomics and genetic engineering.
